Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica
Toxoplasmosis and amebiasis are important public health concerns worldwide. The drugs currently available to control these diseases have proven limitations. Therefore, innovative approaches should be adopted to identify and develop new leads from novel scaffolds exhibiting novel modes of action. In...
Gespeichert in:
| Veröffentlicht in: | Antimicrobial agents and chemotherapy 2014-10, Vol.58 (10), p.5848-5854 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5854 |
|---|---|
| container_issue | 10 |
| container_start_page | 5848 |
| container_title | Antimicrobial agents and chemotherapy |
| container_volume | 58 |
| creator | Boyom, Fabrice F Fokou, Patrick V T Tchokouaha, Lauve R Y Spangenberg, Thomas Mfopa, Alvine N Kouipou, Ruffin M T Mbouna, Cedric J Donfack, Valerie F Donkeng Zollo, Paul H A |
| description | Toxoplasmosis and amebiasis are important public health concerns worldwide. The drugs currently available to control these diseases have proven limitations. Therefore, innovative approaches should be adopted to identify and develop new leads from novel scaffolds exhibiting novel modes of action. In this paper, we describe results from the screening of compounds in the Medicines for Malaria Venture (MMV) open access Malaria Box in a search for new anti-Toxoplasma and anti-Entamoeba agents. Standard in vitro phenotypic screening procedures were adopted to assess their biological activities. Seven anti-Toxoplasma compounds with a 50% inhibitory concentration (IC50) of 6 were identified. The most interesting compound was MMV007791, a piperazine acetamide, which has an IC50 of 0.19 μM and a selectivity index of >157. Also, we identified two compounds, MMV666600 and MMV006861, with modest activities against Entamoeba histolytica, with IC50s of 10.66 μM and 15.58 μM, respectively. The anti-Toxoplasma compounds identified in this study belong to scaffold types different from those of currently used drugs, underscoring their novelty and potential as starting points for the development of new antitoxoplasmosis drugs with novel modes of action. |
| doi_str_mv | 10.1128/AAC.02541-14 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4187973</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1622599156</sourcerecordid><originalsourceid>FETCH-LOGICAL-a517t-d37fa4000eb9b5a7f77df06c00297ad78d0c00fbdf30ee19b492d013104364c93</originalsourceid><addsrcrecordid>eNqFkUFrFTEUhYMo9lnduZYsFZyazCSZyUZ4PKoVCoLUdbgzybyXMpM7JpnS_nujry26EFc3l3wczj2HkNecnXFedx-2290Zq6XgFRdPyIYz3VVKavWUbBhTqhIdEyfkRUrXrOxSs-fkpJZM6FrqDcnf3LLGBZMPe5oPjuLiAoVhcCnRGSaIHmiPtzQjtT4NeOMiXTC7kKkPB9_7jDFRHOkV3uIyQZqB7jFY7ykES89DhhldD_TgU8bpLvsBXpJnI0zJvbqfp-T7p_Or3UV1-fXzl932sgLJ21zZph1BFNeu172EdmxbOzI1MFbrFmzbWVbeY2_HhjnHdV9usow3nIlGiUE3p-TjUXdZ-9nZoZiOMJkl-hninUHw5u-f4A9mjzdG8K7VbVME3t4LRPyxupTNXDJw0wTB4ZoMV3VJUXOp_o9KVSslatkV9P0RHSKmFN346Igz86tTUzo1vzs1XBT83REv2dbmGtcYSmj_Yt_8efGj8EPhzU8dxat1</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1562664258</pqid></control><display><type>article</type><title>Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Boyom, Fabrice F ; Fokou, Patrick V T ; Tchokouaha, Lauve R Y ; Spangenberg, Thomas ; Mfopa, Alvine N ; Kouipou, Ruffin M T ; Mbouna, Cedric J ; Donfack, Valerie F Donkeng ; Zollo, Paul H A</creator><creatorcontrib>Boyom, Fabrice F ; Fokou, Patrick V T ; Tchokouaha, Lauve R Y ; Spangenberg, Thomas ; Mfopa, Alvine N ; Kouipou, Ruffin M T ; Mbouna, Cedric J ; Donfack, Valerie F Donkeng ; Zollo, Paul H A</creatorcontrib><description>Toxoplasmosis and amebiasis are important public health concerns worldwide. The drugs currently available to control these diseases have proven limitations. Therefore, innovative approaches should be adopted to identify and develop new leads from novel scaffolds exhibiting novel modes of action. In this paper, we describe results from the screening of compounds in the Medicines for Malaria Venture (MMV) open access Malaria Box in a search for new anti-Toxoplasma and anti-Entamoeba agents. Standard in vitro phenotypic screening procedures were adopted to assess their biological activities. Seven anti-Toxoplasma compounds with a 50% inhibitory concentration (IC50) of <5 μM and selectivity indexes (SI) of >6 were identified. The most interesting compound was MMV007791, a piperazine acetamide, which has an IC50 of 0.19 μM and a selectivity index of >157. Also, we identified two compounds, MMV666600 and MMV006861, with modest activities against Entamoeba histolytica, with IC50s of 10.66 μM and 15.58 μM, respectively. The anti-Toxoplasma compounds identified in this study belong to scaffold types different from those of currently used drugs, underscoring their novelty and potential as starting points for the development of new antitoxoplasmosis drugs with novel modes of action.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.02541-14</identifier><identifier>PMID: 25049259</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Antiprotozoal Agents ; Antiprotozoal Agents - pharmacology ; Entamoeba histolytica ; Entamoeba histolytica - drug effects ; Parasitic Sensitivity Tests ; Piperazines - pharmacology ; Susceptibility ; Toxoplasma ; Toxoplasma - drug effects ; Toxoplasma gondii</subject><ispartof>Antimicrobial agents and chemotherapy, 2014-10, Vol.58 (10), p.5848-5854</ispartof><rights>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</rights><rights>Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a517t-d37fa4000eb9b5a7f77df06c00297ad78d0c00fbdf30ee19b492d013104364c93</citedby><cites>FETCH-LOGICAL-a517t-d37fa4000eb9b5a7f77df06c00297ad78d0c00fbdf30ee19b492d013104364c93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187973/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187973/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25049259$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boyom, Fabrice F</creatorcontrib><creatorcontrib>Fokou, Patrick V T</creatorcontrib><creatorcontrib>Tchokouaha, Lauve R Y</creatorcontrib><creatorcontrib>Spangenberg, Thomas</creatorcontrib><creatorcontrib>Mfopa, Alvine N</creatorcontrib><creatorcontrib>Kouipou, Ruffin M T</creatorcontrib><creatorcontrib>Mbouna, Cedric J</creatorcontrib><creatorcontrib>Donfack, Valerie F Donkeng</creatorcontrib><creatorcontrib>Zollo, Paul H A</creatorcontrib><title>Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description>Toxoplasmosis and amebiasis are important public health concerns worldwide. The drugs currently available to control these diseases have proven limitations. Therefore, innovative approaches should be adopted to identify and develop new leads from novel scaffolds exhibiting novel modes of action. In this paper, we describe results from the screening of compounds in the Medicines for Malaria Venture (MMV) open access Malaria Box in a search for new anti-Toxoplasma and anti-Entamoeba agents. Standard in vitro phenotypic screening procedures were adopted to assess their biological activities. Seven anti-Toxoplasma compounds with a 50% inhibitory concentration (IC50) of <5 μM and selectivity indexes (SI) of >6 were identified. The most interesting compound was MMV007791, a piperazine acetamide, which has an IC50 of 0.19 μM and a selectivity index of >157. Also, we identified two compounds, MMV666600 and MMV006861, with modest activities against Entamoeba histolytica, with IC50s of 10.66 μM and 15.58 μM, respectively. The anti-Toxoplasma compounds identified in this study belong to scaffold types different from those of currently used drugs, underscoring their novelty and potential as starting points for the development of new antitoxoplasmosis drugs with novel modes of action.</description><subject>Antiprotozoal Agents</subject><subject>Antiprotozoal Agents - pharmacology</subject><subject>Entamoeba histolytica</subject><subject>Entamoeba histolytica - drug effects</subject><subject>Parasitic Sensitivity Tests</subject><subject>Piperazines - pharmacology</subject><subject>Susceptibility</subject><subject>Toxoplasma</subject><subject>Toxoplasma - drug effects</subject><subject>Toxoplasma gondii</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFrFTEUhYMo9lnduZYsFZyazCSZyUZ4PKoVCoLUdbgzybyXMpM7JpnS_nujry26EFc3l3wczj2HkNecnXFedx-2290Zq6XgFRdPyIYz3VVKavWUbBhTqhIdEyfkRUrXrOxSs-fkpJZM6FrqDcnf3LLGBZMPe5oPjuLiAoVhcCnRGSaIHmiPtzQjtT4NeOMiXTC7kKkPB9_7jDFRHOkV3uIyQZqB7jFY7ykES89DhhldD_TgU8bpLvsBXpJnI0zJvbqfp-T7p_Or3UV1-fXzl932sgLJ21zZph1BFNeu172EdmxbOzI1MFbrFmzbWVbeY2_HhjnHdV9usow3nIlGiUE3p-TjUXdZ-9nZoZiOMJkl-hninUHw5u-f4A9mjzdG8K7VbVME3t4LRPyxupTNXDJw0wTB4ZoMV3VJUXOp_o9KVSslatkV9P0RHSKmFN346Igz86tTUzo1vzs1XBT83REv2dbmGtcYSmj_Yt_8efGj8EPhzU8dxat1</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Boyom, Fabrice F</creator><creator>Fokou, Patrick V T</creator><creator>Tchokouaha, Lauve R Y</creator><creator>Spangenberg, Thomas</creator><creator>Mfopa, Alvine N</creator><creator>Kouipou, Ruffin M T</creator><creator>Mbouna, Cedric J</creator><creator>Donfack, Valerie F Donkeng</creator><creator>Zollo, Paul H A</creator><general>American Society for Microbiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>F1W</scope><scope>FR3</scope><scope>H95</scope><scope>H97</scope><scope>L.G</scope><scope>M7N</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20141001</creationdate><title>Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica</title><author>Boyom, Fabrice F ; Fokou, Patrick V T ; Tchokouaha, Lauve R Y ; Spangenberg, Thomas ; Mfopa, Alvine N ; Kouipou, Ruffin M T ; Mbouna, Cedric J ; Donfack, Valerie F Donkeng ; Zollo, Paul H A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a517t-d37fa4000eb9b5a7f77df06c00297ad78d0c00fbdf30ee19b492d013104364c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antiprotozoal Agents</topic><topic>Antiprotozoal Agents - pharmacology</topic><topic>Entamoeba histolytica</topic><topic>Entamoeba histolytica - drug effects</topic><topic>Parasitic Sensitivity Tests</topic><topic>Piperazines - pharmacology</topic><topic>Susceptibility</topic><topic>Toxoplasma</topic><topic>Toxoplasma - drug effects</topic><topic>Toxoplasma gondii</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boyom, Fabrice F</creatorcontrib><creatorcontrib>Fokou, Patrick V T</creatorcontrib><creatorcontrib>Tchokouaha, Lauve R Y</creatorcontrib><creatorcontrib>Spangenberg, Thomas</creatorcontrib><creatorcontrib>Mfopa, Alvine N</creatorcontrib><creatorcontrib>Kouipou, Ruffin M T</creatorcontrib><creatorcontrib>Mbouna, Cedric J</creatorcontrib><creatorcontrib>Donfack, Valerie F Donkeng</creatorcontrib><creatorcontrib>Zollo, Paul H A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Engineering Research Database</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boyom, Fabrice F</au><au>Fokou, Patrick V T</au><au>Tchokouaha, Lauve R Y</au><au>Spangenberg, Thomas</au><au>Mfopa, Alvine N</au><au>Kouipou, Ruffin M T</au><au>Mbouna, Cedric J</au><au>Donfack, Valerie F Donkeng</au><au>Zollo, Paul H A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><stitle>Antimicrob Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>58</volume><issue>10</issue><spage>5848</spage><epage>5854</epage><pages>5848-5854</pages><issn>0066-4804</issn><eissn>1098-6596</eissn><abstract>Toxoplasmosis and amebiasis are important public health concerns worldwide. The drugs currently available to control these diseases have proven limitations. Therefore, innovative approaches should be adopted to identify and develop new leads from novel scaffolds exhibiting novel modes of action. In this paper, we describe results from the screening of compounds in the Medicines for Malaria Venture (MMV) open access Malaria Box in a search for new anti-Toxoplasma and anti-Entamoeba agents. Standard in vitro phenotypic screening procedures were adopted to assess their biological activities. Seven anti-Toxoplasma compounds with a 50% inhibitory concentration (IC50) of <5 μM and selectivity indexes (SI) of >6 were identified. The most interesting compound was MMV007791, a piperazine acetamide, which has an IC50 of 0.19 μM and a selectivity index of >157. Also, we identified two compounds, MMV666600 and MMV006861, with modest activities against Entamoeba histolytica, with IC50s of 10.66 μM and 15.58 μM, respectively. The anti-Toxoplasma compounds identified in this study belong to scaffold types different from those of currently used drugs, underscoring their novelty and potential as starting points for the development of new antitoxoplasmosis drugs with novel modes of action.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>25049259</pmid><doi>10.1128/AAC.02541-14</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0066-4804 |
| ispartof | Antimicrobial agents and chemotherapy, 2014-10, Vol.58 (10), p.5848-5854 |
| issn | 0066-4804 1098-6596 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4187973 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antiprotozoal Agents Antiprotozoal Agents - pharmacology Entamoeba histolytica Entamoeba histolytica - drug effects Parasitic Sensitivity Tests Piperazines - pharmacology Susceptibility Toxoplasma Toxoplasma - drug effects Toxoplasma gondii |
| title | Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T22%3A02%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Repurposing%20the%20open%20access%20malaria%20box%20to%20discover%20potent%20inhibitors%20of%20Toxoplasma%20gondii%20and%20Entamoeba%20histolytica&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=Boyom,%20Fabrice%20F&rft.date=2014-10-01&rft.volume=58&rft.issue=10&rft.spage=5848&rft.epage=5854&rft.pages=5848-5854&rft.issn=0066-4804&rft.eissn=1098-6596&rft_id=info:doi/10.1128/AAC.02541-14&rft_dat=%3Cproquest_pubme%3E1622599156%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1562664258&rft_id=info:pmid/25049259&rfr_iscdi=true |